Mizuho Maintains Outperform on WAVE Life Sciences, Lowers Price Target to $23

Benzinga · 1d ago
Mizuho analyst Salim Syed maintains WAVE Life Sciences (NASDAQ:WVE) with a Outperform and lowers the price target from $27 to $23.